

NCI's Office of Cancer Nanotechnology Research Pre-application Question/Answer Meeting Details and FAQ's for U01

NCI's OCNR recently announced new funding opportunities including the *Innovative Research in Cancer Nanotechnology (IRCN) – U01 (PAR-14-285)*, which allows for foreign, non-U.S. applicants. In order to help foreign, non-U.S. applicants (PD/PIs) in the process of submitting their applications, we will hold one “pre-application” question and answer meeting, which will be publically accessible, on **Friday September 5th, 2014**.

Please read the following information carefully. It includes the times for each meeting, the three ways to attend / communicate during each meeting, and a frequently asked question (FAQ) section to help answer a few commonly asked questions before the meeting.

--For all NIH VideoCast links please test your browser prior to the meeting [here](#). The VideoCast will allow for questions to be written in the ***Live Feedback Form*** during the meeting ([FAQs pertaining to NIH VideoCast](#)). The questions will be immediately relayed to the panel.--

Pre-application Informational Webinar for PAR-14-285 IRCNs (U01)-Foreign (Non-U.S.) Institutions/Applicants

September 5, 2014, 9:30–10:30 am EDT

NIH VideoCast: [U01 Foreign Q&A Meeting here](#)

Teleconference Call-in: See telephone number list by country for telecom at end of this document and use passcode **6705578**

NIH Campus Bethesda, MD Natcher Auditorium, Rm. H*

*Due to the limited seating available in this room, we strongly encourage applicants to attend remotely via VideoCast, teleconference, or both simultaneously.

Frequently Asked Questions (FAQs)

A good place to start, for applicants who are unfamiliar with the application process at the National Cancer Institute, is on the NCI website at [this link](#) for general NCI research and funding FAQs. FAQs specific to the funding opportunities being discussed in this meeting are as follows:

FAQs for IRCNs (U01)

- **Q - What are the objectives of the U01s (IRCNs) under this PAR?**
- A - The IRCNs are expected to expand the fundamental understanding of the processes pertinent to the use of nanotechnology in cancer. Clinical translation is NOT a goal of IRCNs.

- **Q - Are foreign (non-U.S. applicants) eligible as PD/PI for this PAR?**
- A - Yes

- **Q - What nanotechnology devices and constructs qualify under this PAR?**
- A - Please carefully review the definition of nanotechnology included in PAR. For example, microfluidic devices (*unless they have nanometer range channels*) do not qualify.

- **Q - What is the maximum award budget and project period allowed?**
- A - Application budgets are limited to \$450K in direct costs per year; Applications may request up to 5 years of support.

- **Q - Can the application include multiple PDs/PIs?**
- A - Given the need for integration of multi-disciplinary efforts in IRCN projects, applicants are encouraged to take advantage of the multiple PD/PI option with one PD/PI representing biology or oncology fields and another PD/PI representing the fields of chemistry, physics, or engineering.

- **Q - Can one institution submit more than one application to the same submission date of this PAR?**
- A - Yes – providing that research areas and teams on both applications are significantly different.

- **Q - What are the differences between the PAR for these U01s (e.g. IRCNs) versus the RFA (CA-09-013) published in 2009, which also solicited U01s (e.g. CNPPs)?**
- A - The primary differences and similarities are:

1. This PAR does NOT have set aside funds allocated as it did for the previous phase's U01 RFA. The funds to support U01 awards will be drawn from RPG (Research Project Grant funds) pool, similarly to standard R01 submissions.
2. This PAR has multiple receipt dates, on a rolling basis, versus the previous U01 RFA, which designated a single receipt date. Please see the announcement ([PAR-14-285](#)) for the specific receipt dates.
3. Scientific review of the current PAR U01 application does remain within NCI and does not go to the NIH Center for Scientific Review (CSR) for peer review, which is the same as the previous RFA U01.

- **Q - Can the PD/PI be a PD/PI on both an IRCN (U01) and the Cancer Nanotechnology Training Center (T32) application at the same time?**
- A - **Yes** – a PD/PI may submit an application for and, if awarded, serve as the PD/PI for both the U01 and T32 (relevant to the Cancer Nanotechnology Training Centers), simultaneously.
- **Q - Can the PD/PI be a PD/PI on both an IRCN (U01) and the Centers of Cancer Nanotechnology Excellence (U54) application at the same time?**
- A - **No** – although, technically, one applicant may apply for an IRCN on the 2nd (or later) due dates while also having applied for the U54, they may NOT serve as the PD/PI, if awarded, simultaneously. However, IRCN applicants/holders can serve as Project leaders, Core directors, or other key personnel within a U54 CCNE application.
- **Q - Is there a particular focus on selected tumor types to be investigated in the U01 and how many of them should be included in the application?**
- A - All IRCN applicants are expected to concentrate their proposed efforts on one or two rationally selected tumor types. The PAR does not make any recommendations when it comes to the selection of tumors under investigation.
- **Q - How does one incorporate a nanomaterial repository into the required data-sharing plan?**
- A – In the Data Sharing Plan, all applicants are expected to address the sharing of nanomaterial data through appropriate publically accessible databases. At least one scientifically qualified person is expected to be designated as the nanomaterial data sharing coordinator after an award has been made. For the purposes of this Funding Opportunity Announcement (FOA), applicants should detail plans for data submission into NCI's cancer Nanotechnology Laboratory ([caNanoLab](#)) data portal, as described in the Cooperative Agreement Terms and Conditions of Award. Standardized text describing data deposition into caNanoLab will be provided on [the caNanoLab FAQ Wiki page](#).

- **Q - I am an applicant based outside of the United States (e.g. foreign, non-U.S. applicant). What else do I need to know with respect to the application process?**
- A - Please visit the [NIH Fogarty International Center's FAQ page](#) prior to the pre-application meeting for a comprehensive list of common questions.

- **Q - Do foreign organizations have an additional step for electronic applications?**
- A - Yes – Foreign organizations must obtain a NATO Commercial and Government Entity code in addition to an Employer ID Number (EIN) and a DUNS number. For more information on registering, see Grants.gov Registration Instructions for Domestic and Foreign Organizations.

- **Q - What is different about the review of foreign applications?**
- A - In addition to standard review criteria, peer reviewers assess the following:
 1. Whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions in other countries that are not readily available in the United States or that augment existing U.S. resources.
 2. Whether the proposed project has specific relevance to the mission and objectives of the NIH and has the potential for significantly advancing health sciences in the United States.
 - This requirement does not apply to applications from U.S. organizations containing a foreign component. For second-level review, NCI must present foreign applications as special issues to the National Cancer Advisory Board (NCAB). The NCAB reviews whether comparable work is being conducted in the U.S.

- **Q - Are there special budget requirements for applications from foreign non-U.S. institutions?**
- A - Yes – Foreign institutions may use an F&A rate of up to 8 percent. See [Grants to Foreign Institutions, International Organizations, and Domestic Grants with Foreign Components](#) for more information.

- **Q - Are there special considerations for foreign non-U.S. institutions with respect to intellectual property and licensing of technologies developed with NIH funds?**
- A - Yes – the best resource to determine what these entail is the [Rights to Subject Inventions Made through Federal Funding to Foreign Entities](#) notice.

The following phone numbers can be used to dial-in during the teleconference from the countries listed. Dial-in then, when prompted, dial passcode **6705578** from a touch tone phone *only*.

<u>Country</u>	Local / Toll Number	Toll Free Number*
Argentina		0800-777-0515
Australia - Sydney	61-2-8205-8123	1-800-659-380
Austria	43-1-92-81-120	0800-005-266
Belgium	32-2-400-9824	0800-3-8744
Canada	1-517-466-2232	1-866-692-3582
Chile		1230-020-2638
China - A		10800-712-1677
China - B		10800-120-1677
Colombia		01800-9-156477
Czech Republic	420-2-25-98-56-73	800-700-235
Denmark	45-7014-0300	8088-8304
Finland	358-9-5424-7178	0-800-9-14607
France - Lyon	33-4-26-69-12-99	080-563-6110
France - Marseille	33-4-86-06-00-99	080-563-6110
France - Paris	33-1-76-74-24-94	080-563-6110
Germany	49-69-2222-4873	0800-664-4254
Greece	30-80-1-100-0698	00800-12-7310
Hong Kong	852-3001-3859	800-933-921
Hungary		06-800-13830
India - A		000-800-852-1264
Indonesia		001-803-011-3973
Ireland	353-1-247-5678	1800-992-935
Israel		1-80-9216159
Italy - Milan	39-02-3600-6016	800-986-993
Japan - Osaka	81-6-7739-4783	0066-33-132424
Japan - Tokyo	81-3-5539-5187	0066-33-132424
Luxembourg	352-27-000-1384	
Malaysia		1-800-81-3069
Mexico		001-866-295-6360
Netherlands	31-20-718-8596	0800-023-1812
New Zealand	64-9-970-4767	0800-450-789
Norway	47-21-590-072	800-15308
Panama		011-001-800-5072111

Poland		00-800-1212569
Portugal		8008-14054
Russia		8-10-8002-0114011
Singapore	65-6883-9226	800-120-4675
Slovak Republic	421-2-322-422-39	
South Africa		080-09-80424
South Korea	82-2-6744-1079	00798-14800-7189
Spain	34-91-414-25-40	800-300-060
Sweden	46-8-566-19-397	0200-884-614
Switzerland	41-44-580-6402	0800-120-039
Taiwan	886-2-2795-7375	00801-137-796
Thailand		001-800-1206-66050
UK - Birmingham	44-121-210-9039	0808-238-6019
UK - Glasgow	44-141-202-3239	0808-238-6019
UK - Leeds	44-113-301-2139	0808-238-6019
UK - London	44-20-3043-2499	0808-238-6019
UK - Manchester	44-161-601-1439	0808-238-6019
Uruguay		000-413-598-3460
Venezuala		0800-1-00-3782

Certain dialing restrictions can apply from specific countries.

* Restrictions may exist when accessing toll free numbers using a mobile telephone. Country toll free phone numbers cannot be used outside of the country listed.